(1)A company’s “qualifying expenditure on in-house direct research and development” means expenditure incurred by it in relation to which each of conditions A to E is met.
(2)Condition A is that the expenditure is—
(a)incurred on staffing costs (see section 1123),
(b)incurred on software or consumable items (see section 1125),
(c)qualifying expenditure on externally provided workers (see section 1127), or
(d)incurred on relevant payments to the subjects of a clinical trial (see section 1140).
(3)Condition B is that the expenditure is attributable to relevant research and development undertaken by the company itself.
(4)Condition C is that any intellectual property created as a result of the research and development to which the expenditure is attributable is, or will be, vested in the company (whether alone or with other persons).
(5)Condition D is that the expenditure is not incurred by the company in carrying on activities which are contracted out to the company by any person.
(6)Condition E is that the expenditure is not subsidised (see section 1138).
(7)See sections 1124, 1126 and 1132 for provision about when expenditure within subsection (2)(a), (b) or (c) is attributable to relevant research and development.